Skip to main content
. 2014 May 25;2014:608930. doi: 10.1155/2014/608930

Figure 5.

Figure 5

Effects of montelukast, pranlukast, and zafirlukast (0.5–20 μM) on cAMP- (a) and cGMP- (b) phosphodiesterase (PDE) activities in neutrophil cytosol. The results are presented as the mean enzyme activities, and vertical lines show SEM (n = 2–5, with three to four replicates for each drug concentration and control system in each experiment). *P < 0.05 for comparison with the corresponding drug-free control system.